Verona Pharma Announces December 2024 Investor Conference Participation

Company Overview - Verona Pharma plc is a biopharmaceutical company focused on developing and commercializing innovative therapies for chronic respiratory diseases with significant unmet medical needs [2] - The company's first commercial product, Ohtuvayre™ (ensifentrine), is the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule [2] - Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma, and other respiratory diseases [2] Upcoming Conferences - Senior management will present a company overview at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, at 12:00 p.m. ET in New York, NY [1] - The company will also present at the 7th Annual Evercore HealthCONx Conference on December 4, 2024, at 3:00 p.m. ET in Miami, FL [1] - A webcast of each conference presentation will be available on the Events and Presentations link on the company's website [1]